H.C. Wainwright & Co., LLC’s Post

We're excited to be present at the Biopharma event in Cork. Visit us at booth 62 to connect with our directors, Mark Crosbie and Gary Tyne CMRP. Engage in discussions about your current challenges, whether it's optimizing asset strategies or implementing effective root cause analysis. We're here to listen and collaborate with you. Biopharma & Life Sciences Connected Live #reliabilityengineering #rootcauseanalysis #assetmanagement #production #maintenance #defectmanagement

How can we help you? For example, is there one #MES issue you, your team, and your organization are tired of talking about? Stop by Exhibit W226 at ISPE Boston, and let’s talk about what you’re tired of talking about. #ISPEBoston #ISPE #Biotechnology #Pharma #LifeSciences

White & Case's global partner promotions have dropped for the fourth year in a row, with the firm announcing it had made up 37 of its lawyers across its international network. This figure of 37 comes after a series of bumper years. Last year, the firm promoted 42 lawyers, which itself was down from 2022 which saw 46 elevated and 2021′s bumper year, which saw a record-breaking 59 make the cut. A third of the new partners located in the Americas, but the EMEA region dominated the new crop with 22 promotions overall, and with the Paris office in particular seeing seven promotions alone. There are also two new partners in Asia-Pacific, both Singapore based. The promotions come into effect on January 1, 2025, and will add to the firm's total partner base, which currently numbers about 800. Full story from Habiba Cullen-Jafar: https://lnkd.in/gakCbFxR

Anyone else see this shareholder letter to Pacira BioSciences, Inc.? Pull quote: "In our view, Pacira’s Board demonstrates an ineffective capital allocation strategy, maintains a dismal M&A track record and lacks strategic oversight. As shareholders, it is not our preference to discuss these issues publicly nor to endeavor to overhaul the Board. Present circumstances – including the dramatic collapse of Pacira’s stock price and how the Company has handled patent litigation and its communication to shareholders regarding the situation thus far – have pushed us to publish this letter." Read full letter here: https://lnkd.in/eWpa65hy We want a rising tide to bring up ALL boats in our space, if you were a consultant here how would you advise? #devicenation

A&O Shearman, post merger, is bucking the recent trend of most of the other biglaw and globallaw firms. The firm is opting out of the two-tier partnership model and is moving toward an all-equity partnership model. There will no longer be non-equity partners at A&O Shearman. The new equity partnership model will have three lockstep stages: entry, current, and star. This will allow the firm to deal with and adjust to the needs of different partners at different stages of their careers. The lockstep within each stage will allow for greater collaboration amongst the partners in that stage and for management to appropriately compensate those who fall into the super partner category. #lockstepequitypartnership

Impact Biomedical, Inc. Announces Pricing of Initial Public Offering    Today marks a significant milestone for Impact BioMedical Inc. (NYSE American: IBO) as we announce the pricing of our initial public offering of 1,500,000 shares at $3.00 per share. Starting today, September 16, 2024, our shares will begin trading on the NYSE American Market under the ticker symbol “IBO.”   The offering is expected to close on September 17, 2024, with an additional 45-day option for underwriters to purchase up to 225,000 more shares, further bolstering our public debut.   As we embark on this exciting chapter, Impact BioMedical remains committed to discovering and developing innovative solutions in human healthcare and wellness. This IPO is a testament to our vision and continued growth as we bring new offerings to market.   https://lnkd.in/eT79gSUK   #ImpactBioMedical #IPO #HealthcareInnovation #NYSE #LifeSciences #IBO Revere Securities

Join my Goodwin colleagues @Caroline Bullerjahn, @Tucker DeVoe and @Justin Ward, and outside speaker @Frank Schneider from Cornerstone Research, as they dive into the key updates and recent trends concerning securities class actions filed against publicly traded life sciences companies. Gain valuable perspectives on recent impactful decisions, potential implications of those decisions, and practical steps you can take to make informed choices for your business. #GoodwinLaw #SecuritiesLitigation #LifeSciences #2024Trends Register here: https://lnkd.in/gK3DX5hy

Impact Biomedical, Inc. Announces Pricing of Initial Public Offering    Today marks a significant milestone for Impact BioMedical Inc. (NYSE American: IBO) as we announce the pricing of our initial public offering of 1,500,000 shares at $3.00 per share. Starting today, September 16, 2024, our shares will begin trading on the NYSE American Market under the ticker symbol “IBO.”   The offering is expected to close on September 17, 2024, with an additional 45-day option for underwriters to purchase up to 225,000 more shares, further bolstering our public debut.   As we embark on this exciting chapter, Impact BioMedical remains committed to discovering and developing innovative solutions in human healthcare and wellness. This IPO is a testament to our vision and continued growth as we bring new offerings to market.   https://lnkd.in/eii5sHPN   #ImpactBioMedical #IPO #HealthcareInnovation #NYSE #LifeSciences #IBO Revere Securities

Yesterday I was asked to summarize my working relationship with a global pharma in China, on RWD/E. One question is, what do you think an ideal relationship should look like, bwt pharma & CRO, in database studies (in China)? This question was not new. I was asked four years ago. My answer was, “trusted partnership”, rather than sponsor-vendor relationship. Imaging you were in the “gold rush” to California 180 years ago, and wanted to hire a guide/bodyguard/cowboy to go with you, do you pre define how many guns he brings, left or right hand? What color is his horse? Exact Milestone payment? What’s the SOP? Working on RWD in China is like gold rush to California. A trusted partnership is desirable, although is not always possible.